A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MGLL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)
Latest Information Update: 01 Feb 2025
Price :
$35 *
At a glance
- Drugs BMS 986368 (Primary)
- Indications Multiple sclerosis; Muscle spasticity
- Focus Therapeutic Use
- Acronyms BALANCE-MSS-1
- Sponsors Celgene Corporation
- 23 Jan 2025 New trial record